Revisiting the role of the innate immune complement system in ALS

Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing motor neuron disease without effective treatment. Although the precise mechanisms leading to ALS are yet to be determined, there is now increasing evidence implicating components of the innate immune complement system in the onse...

Full description

Saved in:
Bibliographic Details
Published in:Neurobiology of disease 2019-07, Vol.127, p.223-232
Main Authors: Parker, Sandra E., Hanton, Angela M., Stefanou, Stephen N., Noakes, Peter G., Woodruff, Trent M., Lee, John D.
Format: Article
Language:English
Subjects:
Amyotrophic Lateral Sclerosis - immunology
Amyotrophic Lateral Sclerosis - metabolism
Animals
Complement System Proteins - metabolism
Humans
Immunity, Innate - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c485t-cbf0ed8d0286ca2438ce8042dc5a5904d56f53d67a4daa1cdbbedb64d0f5da8a3
cites cdi_FETCH-LOGICAL-c485t-cbf0ed8d0286ca2438ce8042dc5a5904d56f53d67a4daa1cdbbedb64d0f5da8a3
container_end_page 232
container_issue
container_start_page 223
container_title Neurobiology of disease
container_volume 127
creator Parker, Sandra E.
Hanton, Angela M.
Stefanou, Stephen N.
Noakes, Peter G.
Woodruff, Trent M.
Lee, John D.
description Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing motor neuron disease without effective treatment. Although the precise mechanisms leading to ALS are yet to be determined, there is now increasing evidence implicating components of the innate immune complement system in the onset and progression of its motor phenotypes. This review will survey the clinical and experimental evidence for the role of the complement system in driving neuroinflammation and contributing to ALS disease progression. Specifically, it will explore findings regarding the different complement activation pathways involved in ALS, with a focus on the terminal pathway. It will also examine potential future research directions for complement in ALS, highlighting the targeting of specific molecular components of the system.
doi_str_mv 10.1016/j.nbd.2019.03.003
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f75d5044e3d94ef0a3e88f45f9dbaad9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0969996119300622</els_id><doaj_id>oai_doaj_org_article_f75d5044e3d94ef0a3e88f45f9dbaad9</doaj_id><sourcerecordid>2189548176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-cbf0ed8d0286ca2438ce8042dc5a5904d56f53d67a4daa1cdbbedb64d0f5da8a3</originalsourceid><addsrcrecordid>eNp9kcFqHDEMhk1paDZpH6CXMsdeZiqP7VmbnpaQtoGFQpNAb8Zjy6mXmfHW9gby9nWySY49SUi_PiH9hHyk0FGgw5ddt4yu64GqDlgHwN6QFQUlWiXY77dkBWpQrVIDPSVnOe8AKBVq_Y6cMpBcCUpXZPML70MOJSx3TfmDTYoTNtE_5WFZTKlhng8LNjbO-wlnXEqTH3LBufabzfb6PTnxZsr44Tmek9tvlzcXP9rtz-9XF5tta7kUpbWjB3TSQS8Ha3rOpEUJvHdWGKGAOzF4wdywNtwZQ60bR3TjwB144Yw07JxcHbkump3epzCb9KCjCfqpENOdNqkEO6H2a-EEcI7MKY4eDEMpPRdeudEYpyrr85G1T_HvAXPRc8gWp8ksGA9Z91QqwSVdD1VKj1KbYs4J_etqCvrRBb3T1QX96IIGpqsLdebTM_4wzuheJ17eXgVfjwKsD7sPmHS2AReLLiS0pV4U_oP_B51cmFQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2189548176</pqid></control><display><type>article</type><title>Revisiting the role of the innate immune complement system in ALS</title><source>ScienceDirect</source><creator>Parker, Sandra E. ; Hanton, Angela M. ; Stefanou, Stephen N. ; Noakes, Peter G. ; Woodruff, Trent M. ; Lee, John D.</creator><creatorcontrib>Parker, Sandra E. ; Hanton, Angela M. ; Stefanou, Stephen N. ; Noakes, Peter G. ; Woodruff, Trent M. ; Lee, John D.</creatorcontrib><description>Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing motor neuron disease without effective treatment. Although the precise mechanisms leading to ALS are yet to be determined, there is now increasing evidence implicating components of the innate immune complement system in the onset and progression of its motor phenotypes. This review will survey the clinical and experimental evidence for the role of the complement system in driving neuroinflammation and contributing to ALS disease progression. Specifically, it will explore findings regarding the different complement activation pathways involved in ALS, with a focus on the terminal pathway. It will also examine potential future research directions for complement in ALS, highlighting the targeting of specific molecular components of the system.</description><identifier>ISSN: 0969-9961</identifier><identifier>EISSN: 1095-953X</identifier><identifier>DOI: 10.1016/j.nbd.2019.03.003</identifier><identifier>PMID: 30849511</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Amyotrophic Lateral Sclerosis - immunology ; Amyotrophic Lateral Sclerosis - metabolism ; Animals ; Complement System Proteins - metabolism ; Humans ; Immunity, Innate - physiology</subject><ispartof>Neurobiology of disease, 2019-07, Vol.127, p.223-232</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-cbf0ed8d0286ca2438ce8042dc5a5904d56f53d67a4daa1cdbbedb64d0f5da8a3</citedby><cites>FETCH-LOGICAL-c485t-cbf0ed8d0286ca2438ce8042dc5a5904d56f53d67a4daa1cdbbedb64d0f5da8a3</cites><orcidid>0000-0002-9976-7396</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0969996119300622$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30849511$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parker, Sandra E.</creatorcontrib><creatorcontrib>Hanton, Angela M.</creatorcontrib><creatorcontrib>Stefanou, Stephen N.</creatorcontrib><creatorcontrib>Noakes, Peter G.</creatorcontrib><creatorcontrib>Woodruff, Trent M.</creatorcontrib><creatorcontrib>Lee, John D.</creatorcontrib><title>Revisiting the role of the innate immune complement system in ALS</title><title>Neurobiology of disease</title><addtitle>Neurobiol Dis</addtitle><description>Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing motor neuron disease without effective treatment. Although the precise mechanisms leading to ALS are yet to be determined, there is now increasing evidence implicating components of the innate immune complement system in the onset and progression of its motor phenotypes. This review will survey the clinical and experimental evidence for the role of the complement system in driving neuroinflammation and contributing to ALS disease progression. Specifically, it will explore findings regarding the different complement activation pathways involved in ALS, with a focus on the terminal pathway. It will also examine potential future research directions for complement in ALS, highlighting the targeting of specific molecular components of the system.</description><subject>Amyotrophic Lateral Sclerosis - immunology</subject><subject>Amyotrophic Lateral Sclerosis - metabolism</subject><subject>Animals</subject><subject>Complement System Proteins - metabolism</subject><subject>Humans</subject><subject>Immunity, Innate - physiology</subject><issn>0969-9961</issn><issn>1095-953X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kcFqHDEMhk1paDZpH6CXMsdeZiqP7VmbnpaQtoGFQpNAb8Zjy6mXmfHW9gby9nWySY49SUi_PiH9hHyk0FGgw5ddt4yu64GqDlgHwN6QFQUlWiXY77dkBWpQrVIDPSVnOe8AKBVq_Y6cMpBcCUpXZPML70MOJSx3TfmDTYoTNtE_5WFZTKlhng8LNjbO-wlnXEqTH3LBufabzfb6PTnxZsr44Tmek9tvlzcXP9rtz-9XF5tta7kUpbWjB3TSQS8Ha3rOpEUJvHdWGKGAOzF4wdywNtwZQ60bR3TjwB144Yw07JxcHbkump3epzCb9KCjCfqpENOdNqkEO6H2a-EEcI7MKY4eDEMpPRdeudEYpyrr85G1T_HvAXPRc8gWp8ksGA9Z91QqwSVdD1VKj1KbYs4J_etqCvrRBb3T1QX96IIGpqsLdebTM_4wzuheJ17eXgVfjwKsD7sPmHS2AReLLiS0pV4U_oP_B51cmFQ</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Parker, Sandra E.</creator><creator>Hanton, Angela M.</creator><creator>Stefanou, Stephen N.</creator><creator>Noakes, Peter G.</creator><creator>Woodruff, Trent M.</creator><creator>Lee, John D.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9976-7396</orcidid></search><sort><creationdate>201907</creationdate><title>Revisiting the role of the innate immune complement system in ALS</title><author>Parker, Sandra E. ; Hanton, Angela M. ; Stefanou, Stephen N. ; Noakes, Peter G. ; Woodruff, Trent M. ; Lee, John D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-cbf0ed8d0286ca2438ce8042dc5a5904d56f53d67a4daa1cdbbedb64d0f5da8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Amyotrophic Lateral Sclerosis - immunology</topic><topic>Amyotrophic Lateral Sclerosis - metabolism</topic><topic>Animals</topic><topic>Complement System Proteins - metabolism</topic><topic>Humans</topic><topic>Immunity, Innate - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parker, Sandra E.</creatorcontrib><creatorcontrib>Hanton, Angela M.</creatorcontrib><creatorcontrib>Stefanou, Stephen N.</creatorcontrib><creatorcontrib>Noakes, Peter G.</creatorcontrib><creatorcontrib>Woodruff, Trent M.</creatorcontrib><creatorcontrib>Lee, John D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Neurobiology of disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parker, Sandra E.</au><au>Hanton, Angela M.</au><au>Stefanou, Stephen N.</au><au>Noakes, Peter G.</au><au>Woodruff, Trent M.</au><au>Lee, John D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revisiting the role of the innate immune complement system in ALS</atitle><jtitle>Neurobiology of disease</jtitle><addtitle>Neurobiol Dis</addtitle><date>2019-07</date><risdate>2019</risdate><volume>127</volume><spage>223</spage><epage>232</epage><pages>223-232</pages><issn>0969-9961</issn><eissn>1095-953X</eissn><abstract>Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing motor neuron disease without effective treatment. Although the precise mechanisms leading to ALS are yet to be determined, there is now increasing evidence implicating components of the innate immune complement system in the onset and progression of its motor phenotypes. This review will survey the clinical and experimental evidence for the role of the complement system in driving neuroinflammation and contributing to ALS disease progression. Specifically, it will explore findings regarding the different complement activation pathways involved in ALS, with a focus on the terminal pathway. It will also examine potential future research directions for complement in ALS, highlighting the targeting of specific molecular components of the system.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30849511</pmid><doi>10.1016/j.nbd.2019.03.003</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-9976-7396</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0969-9961
ispartof Neurobiology of disease, 2019-07, Vol.127, p.223-232
issn 0969-9961
1095-953X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_f75d5044e3d94ef0a3e88f45f9dbaad9
source ScienceDirect
subjects Amyotrophic Lateral Sclerosis - immunology
Amyotrophic Lateral Sclerosis - metabolism
Animals
Complement System Proteins - metabolism
Humans
Immunity, Innate - physiology
title Revisiting the role of the innate immune complement system in ALS
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A40%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revisiting%20the%20role%20of%20the%20innate%20immune%20complement%20system%20in%20ALS&rft.jtitle=Neurobiology%20of%20disease&rft.au=Parker,%20Sandra%20E.&rft.date=2019-07&rft.volume=127&rft.spage=223&rft.epage=232&rft.pages=223-232&rft.issn=0969-9961&rft.eissn=1095-953X&rft_id=info:doi/10.1016/j.nbd.2019.03.003&rft_dat=%3Cproquest_doaj_%3E2189548176%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-cbf0ed8d0286ca2438ce8042dc5a5904d56f53d67a4daa1cdbbedb64d0f5da8a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2189548176&rft_id=info:pmid/30849511&rfr_iscdi=true